Pertussis Acellular Vaccine Component
Pertussis acellular vaccine component consists of purified antigens such as pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin, used in combination vaccines for prophylaxis. It is a toxin or culture-derived product for prophylactic mixing, classified under tariff item 3002.49.00 as 'Other' vaccines, toxins, or cultures of micro-organisms.
Import Duty Rates by Country of Origin
| Origin Country | MFN Tariff | Surtaxes | Total Effective Rate |
|---|---|---|---|
| π¨π³China | Free | β | Free |
| π²π½Mexico | Free | β | Free |
| πΊπΈUnited States | Free | β | Free |
| π©πͺGermany | Free | β | Free |
| π―π΅Japan | Free | β | Free |
More Specific Codes
This product may fall under a more specific subheading:
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If the component is in measured doses or for retail sale
If the antigen is packaged in measured doses, subheading 3002.15 for immunological products may apply.
If the component is a toxin or culture not classified as a vaccine
Subheading 3002.90 covers other similar products, which could include purified antigens if not considered vaccines.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right tariff item β and can price the duty on it in the same conversation.
Import Tips & Compliance
β’ Ensure the component is imported for use in a licensed vaccine product and has the necessary Health Canada approval
β’ Declare the product under 3002.49.00 and provide technical documentation on the antigen composition to support classification
β’ Verify if the product is duty-free under the MFN tariff, but confirm with the CBSA for current rates
Related Products under Tariff item 3002.49.00
Anthrax Vaccine Adsorbed (AVA)
Anthrax Vaccine Adsorbed (AVA), known as BioThrax, is a cell-free vaccine prepared from protective antigen of Bacillus anthracis adsorbed to aluminum hydroxide. It is used to induce immunity against anthrax in military personnel and emergency responders. This vaccine falls under tariff item 3002.49.00 as an 'other' vaccine derived from micro-organisms, not specifically named elsewhere in the subheading.
Biotechnological Ricin for Immunological Studies
Recombinant ricin toxin produced through biotechnological processes for studying immune responses and antibody production. It is a modified toxin used in laboratory research to investigate immunological mechanisms and develop diagnostic or therapeutic applications. This product falls under tariff item 3002.49.00 as an 'other' toxin or similar product obtained by means of biotechnological processes.
Castor-Derived Ricin for Biodefense Countermeasures
Ricin extracted from castor beans for biodefense programs developing countermeasures. This toxin is used in prophylactic research by government laboratories to develop vaccines or antitoxins. It is classified under tariff item 3002.49.00 as an 'other' toxin obtained by biotechnological processes for prophylactic purposes.
Chlamydia Vaccine (Recombinant)
This recombinant chlamydia vaccine uses the major outer membrane protein (MOMP) produced through biotechnological processes, combined with an adjuvant. It is designed to prevent trachoma and sexually transmitted chlamydial infections. As a vaccine obtained by biotechnological means, it is classified under tariff item 3002.49.00 as an 'other' vaccine.
Cholera Oral Vaccine
Inactivated oral vaccine with recombinant B-subunit and killed whole cells for cholera prevention in travelers. This vaccine is a microbial culture-based product for prophylactic human use and is not a yeast. It is classified under tariff item 3002.49.00 as an 'other' vaccine.
Cholera Vaccine (Oral Recombinant)
Dukoral is an oral cholera vaccine containing inactivated Vibrio cholerae whole cells and recombinant cholera toxin B subunit. It provides mucosal immunity against cholera and is administered as an oral suspension with a buffer solution. This vaccine is classified under tariff item 3002.49.00 as an 'other' vaccine, as it is not specifically named in other subheadings.